Appendix 1.
Search(prostate cancer with metastatic with cost) AND ("2012/01/01"[Date - Publication] : "2016/10/09"[Date - Publication])
Select item 276350241.
Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer.
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
J Nucl Med. 2016 Sep 15. pii: jnumed.116.178939. [Epub ahead of print]
Select item 276248752.
Socioeconomic Differences in Use of Low-Value Cancer Screenings and Distributional Effects in Medicare.
Xu WY, Jung JK.
Health Serv Res. 2016 Sep 13. doi: 10.1111/1475-6773.12559. [Epub ahead of print]
Select item 276197773.
Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales, Australia.
Cronin P, Kirkbride B, Bang A, Parkinson B, Smith D, Haywood P.
Asia Pac J Clin Oncol. 2016 Sep 13. doi: 10.1111/ajco.12582. [Epub ahead of print]
Select item 275709994.
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.
J Med Econ. 2016 Sep 16:1-8. [Epub ahead of print]
Select item 275666995.
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-ResistantProstate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BL, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.
Pharmacoeconomics. 2016 Aug 26. [Epub ahead of print] Review.
Select item 275636576.
Immunobiology and immunotherapy in genitourinary malignancies.
Tsiatas M, Grivas P.
Ann Transl Med. 2016 Jul;4(14):270. doi: 10.21037/atm.2016.06.29. Review.
Select item 275347987.
Proton beam therapy in Japan: current and future status.
Sakurai H, Ishikawa H, Okumura T.
Jpn J Clin Oncol. 2016 Aug 17. [Epub ahead of print] Review.
Select item 275301568.
Nurse-led group consultation intervention reduces depressive symptoms in men with localisedprostate cancer: a cluster randomised controlled trial.
Schofield P, Gough K, Lotfi-Jam K, Bergin R, Ugalde A, Dudgeon P, Crellin W, Schubach K, Foroudi F, Tai KH, Duchesne G, Sanson-Fisher R, Aranda S.
BMC Cancer. 2016 Aug 16;16:637. doi: 10.1186/s12885-016-2687-1.
Select item 274573099.
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.
Cherny N, Sullivan R, Torode J, Saar M, Eniu A.
Ann Oncol. 2016 Aug;27(8):1423-43. doi: 10.1093/annonc/mdw213.
Select item 2743459510.
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.
Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530.
Select item 2742270911.
Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies.
Volik S, Alcaide M, Morin RD, Collins CC.
Mol Cancer Res. 2016 Jul 15. pii: molcanres.0044.2016. [Epub ahead of print]
Select item 2740403912.
Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide.
Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES.
Prostate. 2016 Jul 12. doi: 10.1002/pros.23232. [Epub ahead of print]
Select item 2739068713.
Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.
Hosseini SA, Rajabi F, Akbari Sari A, Ayati M, Heidari S, Ghamary F.
Med J Islam Repub Iran. 2016 Jan 9;30:317. eCollection 2016.
Select item 2737720714.
Do skeletal-related events predict overall survival in men with metastatic castration-resistantprostate cancer?
Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ.
Prostate Cancer Prostatic Dis. 2016 Jul 5. doi: 10.1038/pcan.2016.26. [Epub ahead of print]
Select item 2734762115.
Robot-assisted versus open radical prostatectomy utilization in hospitals offering robotics.
Yanamadala S, Chung BI, Hernandez-Boussard TM.
Can J Urol. 2016 Jun;23(3):8279-84.
Select item 2726427816.
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S, Chakravarty R, Shetty P, Vimalnath KV, Sen IB, Dash A.
J Labelled Comp Radiopharm. 2016 Jul;59(9):364-71. doi: 10.1002/jlcr.3414. Epub 2016 Jun 6.
Select item 2725601617.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.
BJU Int. 2016 Jun 3. doi: 10.1111/bju.13549. [Epub ahead of print]
Select item 2723294318.
Functional/activity network (FAN) analysis of gene-phenotype connectivity liaised by grape polyphenol resveratrol.
Hsieh TC, Wu ST, Bennett DJ, Doonan BB, Wu E, Wu JM.
Oncotarget. 2016 May 24. doi: 10.18632/oncotarget.9578. [Epub ahead of print]
Select item 2717487019.
Economic evaluation of single-fraction versus multiple-fraction palliative radiotherapy for painful bone metastases in breast, lung and prostate cancer.
Collinson L, Kvizhinadze G, Nair N, McLeod M, Blakely T.
J Med Imaging Radiat Oncol. 2016 Oct;60(5):650-660. doi: 10.1111/1754-9485.12467.
Select item 2714549320.
Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR, Wen F, Wu YF, Wheeler JR, Li Q.
Eur J Cancer Care (Engl). 2016 May 3. doi: 10.1111/ecc.12505. [Epub ahead of print]
Select item 2713016721.
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing forProstate cancer (CAP).
Thorn JC, Turner EL, Hounsome L, Walsh E, Down L, Verne J, Donovan JL, Neal DE, Hamdy FC, Martin RM, Noble SM; CAP trial group.
BMJ Open. 2016 Apr 29;6(4):e011063. doi: 10.1136/bmjopen-2016-011063.
Select item 2710982722.
Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
Svensson J, Andersson E, Persson U, Edekling T, Ovanfors A, Ahlgren G.
Scand J Urol. 2016 Aug;50(4):286-91. doi: 10.3109/21681805.2016.1172254. Epub 2016 Apr 25.
Select item 2703125523.
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Pilon D, Queener M, Lefebvre P, Ellis LA.
J Med Econ. 2016 Aug;19(8):777-84. doi: 10.3111/13696998.2016.1173042. Epub 2016 Apr 20.
Select item 2701525524.
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN, O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, Popelar B, Tang H, Balk M.
J Manag Care Spec Pharm. 2016 Feb;22(2):163-70. doi: 10.18553/jmcp.2016.22.2.163.
Select item 2697262625.
A nationwide epidemiological study of newly diagnosed spine metastasis in the adult Korean population.
Sohn S, Kim J, Chung CK, Lee NR, Park E, Chang UK, Sohn MJ, Kim SH.
Spine J. 2016 Aug;16(8):937-45. doi: 10.1016/j.spinee.2016.03.006. Epub 2016 Mar 10.
Select item 2688065826.
Initial experience of an algorithm-based protocol for the community follow-up of men with prostate cancer.
Goodall PP, Little J, Robinson E, Trimble I, Cole OJ, Walton TJ.
BJU Int. 2016 Feb 15. doi: 10.1111/bju.13446. [Epub ahead of print]
Select item 2686559127.
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees WithProstate Cancer Metastatic to Bone.
McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, Greenlee S, Valderrama A, Sullivan SD, Ramsey SD.
Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.
Select item 2686539228.
Health resource utilisation associated with skeletal-related events in patients with bone metastasessecondary to solid tumours: regional comparisons in an observational study.
Duran I, Fink MG, Bahl A, Hoefeler H, Mahmood A, Lüftner D, Ghazal H, Wei R, Chung KC, Hechmati G, Green J, Atchison C.
Eur J Cancer Care (Engl). 2016 Feb 10. doi: 10.1111/ecc.12452. [Epub ahead of print]
Select item 2686291129.
The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist.
Guirgis HM.
J Community Support Oncol. 2015 Oct;13(10):362-6. doi: 10.12788/jcso.0148.
Select item 2684938130.
Cost of skeletal complications from bone metastases in six European countries.
Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R.
J Med Econ. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016 Feb 23.
Select item 2683236331.
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111-21. doi: 10.1038/pcan.2015.42. Epub 2016 Feb 2. Review.
Select item 2682871632.
Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
Sanyal C, Aprikian AG, Cury FL, Chevalier S, Dragomir A.
Cancer. 2016 Apr 1;122(7):1085-96. doi: 10.1002/cncr.29892. Epub 2016 Feb 1.
Select item 2679472933.
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ.
JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570.
Select item 2679387534.
[Advancement in the treatment against prostate cancer].
Shinohara N, Abe T, Maruyama S.
Nihon Rinsho. 2016 Jan;74(1):27-33. Japanese.
Select item 2678007335.
[Direct and indirect costs of luteinising hormone-releasing hormone analogues in the treatment of locally advanced or metastatic prostate cancer in Italy].
Fadda V, Maratea D.
Recenti Prog Med. 2015 Dec;106(12):634-40. doi: 10.1701/2094.22656. Italian.
Select item 2668680236.
Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ, Kerr C, Penton J, Knerer G.
Value Health. 2015 Dec;18(8):1152-7. doi: 10.1016/j.jval.2015.08.012. Epub 2015 Oct 21.
Select item 2666640937.
Prostatectomy at high-volume centers improves outcomes and lowers the costs of care forprostate cancer.
Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S.
Prostate Cancer Prostatic Dis. 2016 Mar;19(1):84-91. doi: 10.1038/pcan.2015.56. Epub 2015 Dec 15.
Select item 2666466138.
Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.
Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):307-14. doi: 10.5489/cuaj.2707.
Select item 2664597539.
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P, Wong YN, Armstrong K, Haas N, Subedi P, Davis-Cerone M, Doshi JA.
Cancer Med. 2016 Feb;5(2):169-81. doi: 10.1002/cam4.574. Epub 2015 Dec 8.
Select item 2661486440.
Management of Prostate Cancer in the Elderly.
Tay KJ, Moul JW, Armstrong AJ.
Clin Geriatr Med. 2016 Feb;32(1):113-32. doi: 10.1016/j.cger.2015.08.001. Epub 2015 Oct 14. Review.
Select item 2658885741.
Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistantprostate cancer.
Dellis A, Papatsoris A.
Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):5-10. doi: 10.1586/14737167.2016.1123624. Review.
Select item 2657304342.
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-ResistantProstate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.
Norum J, Traasdahl ER, Totth A, Nieder C, Olsen JA.
Glob J Health Sci. 2015 Jul 30;8(4):1-9. doi: 10.5539/gjhs.v8n4p1. Review.
Select item 2653266543.
Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With MetastaticCastration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial.
Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S.
Value Health. 2015 Nov;18(7):A475. doi: 10.1016/j.jval.2015.09.1270. Epub 2015 Oct 20. No abstract available.
Select item 2653266144.
Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve MetastaticCastration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt).
Vicente C, Loblaw A, North S, Kassouf W, Naidoo S, Husein F, Nakhaipour HR.
Value Health. 2015 Nov;18(7):A474. doi: 10.1016/j.jval.2015.09.1266. Epub 2015 Oct 20. No abstract available.
Select item 2653258545.
Health Economics And Radium-223 (Xofigo®) In The Treatment Of Metastatic Castration-Resistant Prostate Cancer (Mcrpc). A Case History And A Systematic Review Of The Literature OnCost-Effectiveness Analysis (Cea).
Norum J, Traasdahl E, Totth A, Nieder C, Olsen JA.
Value Health. 2015 Nov;18(7):A460-1. doi: 10.1016/j.jval.2015.09.1191. Epub 2015 Oct 20. No abstract available.
Select item 2653258146.
Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate CancerPreviously Treated With Docetaxel.
Gaultney J, Baka A, Leliveld-Kors A, Noordzij W, Wyndaele D, De Meyer C.
Value Health. 2015 Nov;18(7):A459. doi: 10.1016/j.jval.2015.09.1184. Epub 2015 Oct 20. No abstract available.
Select item 2653251047.
A Cost Comparison of Treatment with Abiraterone Acetate Plus Prednisone in the Pre Chemotherapy Setting Followed By Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration Resistant Prostate Cancer Patients With non-Visceral Metastases.
Dearden L, Girod I, Majer I, van de Wetering G.
Value Health. 2015 Nov;18(7):A446. doi: 10.1016/j.jval.2015.09.1109. Epub 2015 Oct 20. No abstract available.
Select item 2653249948.
Do Payers Equally Value the Cost Per Month of Overall Survival for Metastatic Castration ResistantProstate Cancer within the Eu5?
Foxon G, Fox G, Craddy P.
Value Health. 2015 Nov;18(7):A444. doi: 10.1016/j.jval.2015.09.1100. Epub 2015 Oct 20. No abstract available.
Select item 2653248949.
Radio-223 in the Treatment of Metastatic Castration Resistant Prostate Cancer with Bone Metastases: Budget Impact Analysis of the National Health Service.
Di Matteo S, Valentino MC, Bruno GM, Colombo GL.
Value Health. 2015 Nov;18(7):A442. doi: 10.1016/j.jval.2015.09.1086. Epub 2015 Oct 20. No abstract available.
Select item 2652070350.
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B.
Eur Urol. 2016 Apr;69(4):720-7. doi: 10.1016/j.eururo.2015.10.007. Epub 2015 Oct 29.
Select item 2651996951.
[Economic evaluation of the treatments of non-metastatic prostate cancer].
Perlbarg J, Rabetrano H, Soulié M, Salomon L, Durand-Zaleski I.
Prog Urol. 2015 Nov;25(15):1108-15. doi: 10.1016/j.purol.2015.07.012. Review. French.
Select item 2649387152.
Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastaticcastrate-resistant prostate cancer.
Patel JM, Holle LM, Clement JM, Bunz T, Niemann C, Chamberlin KW.
J Oncol Pharm Pract. 2015 Oct 22. pii: 1078155215612541. [Epub ahead of print]
Select item 2648276853.
Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.
Boyd KA, Jones RJ, Paul J, Birrell F, Briggs AH, Leung HY.
BMJ Open. 2015 Oct 19;5(10):e007925. doi: 10.1136/bmjopen-2015-007925. Erratum in: BMJ Open. 2016;6(8):e007925corr1.
Select item 2647080654.
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.
Winn AN, Ekwueme DU, Guy GP Jr, Neumann PJ.
Am J Prev Med. 2016 Feb;50(2):241-8. doi: 10.1016/j.amepre.2015.08.009. Epub 2015 Oct 23. Review.
Select item 2645146555.
A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G, Sendur MA, Aksoy S, Sever AR, Altundag K.
Curr Med Res Opin. 2016;32(1):133-45. doi: 10.1185/03007995.2015.1105795. Epub 2015 Nov 25. Review.
Select item 2640918756.
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
ICECaP Working Group, Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B.
J Natl Cancer Inst. 2015 Sep 25;107(12):djv261. doi: 10.1093/jnci/djv261. Print 2015 Dec.
Select item 2640309257.
Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S, Toumi M.
BioDrugs. 2015 Oct;29(5):301-7. doi: 10.1007/s40259-015-0140-7.
Select item 2633170958.
Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A, Almehmadi Y, Saad F, Doros G, Gooren L.
Clin Endocrinol (Oxf). 2016 Jan;84(1):107-14. doi: 10.1111/cen.12936. Epub 2015 Oct 2.
Select item 2625358459.
Health resource utilization associated with skeletal-related events: results from a retrospective European study.
Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R.
Eur J Health Econ. 2016 Jul;17(6):711-21. doi: 10.1007/s10198-015-0716-7. Epub 2015 Aug 8.
Select item 2624173360.
Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer.
Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD.
J Palliat Med. 2015 Nov;18(11):933-9. doi: 10.1089/jpm.2015.0171. Epub 2015 Aug 4.
Select item 2621313861.
Prostate cancer as a chronic disease: cost-effectiveness and proper follow-up.
Guttilla A, Bortolami A, Evangelista L.
Q J Nucl Med Mol Imaging. 2015 Dec;59(4):439-45. Epub 2015 Jul 24. Review.
Select item 2615754062.
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.
Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.
Am Health Drug Benefits. 2015 Jun;8(4):185-95.
Select item 2615058663.
Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms.
Pokuri VK, Nourkeyhani H, Betsy B, Herbst L, Sikorski M, Spangenthal E, Fabiano A, George S.
J Natl Compr Canc Netw. 2015 Jul;13(7):e49-55.
Select item 2609167464.
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Graff JN, Beer TM.
Oncology (Williston Park). 2015 Jun;29(6):416-23. Review.
Select item 2608967965.
Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients withmetastatic castration-resistant prostate cancer.
Renzulli JF 2nd, Collins J, Mega A.
J Multidiscip Healthc. 2015 Jun 5;8:279-86. doi: 10.2147/JMDH.S81007. eCollection 2015.
Select item 2608283766.
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A.
J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015.
Select item 2607438267.
Prostate cancer.
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS.
Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11. Review.
Select item 2605612068.
The utility of Google Trends data to examine interest in cancer screening.
Schootman M, Toor A, Cavazos-Rehg P, Jeffe DB, McQueen A, Eberth J, Davidson NO.
BMJ Open. 2015 Jun 8;5(6):e006678. doi: 10.1136/bmjopen-2014-006678.
Select item 2602137169.
[Brachytherapy for Prostate Cancer: Potentials and Limitations of Social Health Insurance Data for Benefit Assessment].
Horenkamp-Sonntag D, Linder R, Engel S, Verheyen F.
Gesundheitswesen. 2016 May;78(5):298-305. doi: 10.1055/s-0034-1398512. Epub 2015 May 28. German.
Select item 2601740170.
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.